The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest pact as part of its “Most Favored Nation” pricing initiative.

North Chicago-based AbbVie has become the latest drugmaker to reach a deal with the Trump administration on drug prices in ...

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

AbbVie’s popular arthritis drug Humira is a powerhouse, producing $14 billion in annual sales to make up 60 percent of the drugmaker’s revenue. However, generic versions of the drug are around the ...

Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...